Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Signaling Pathway Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FAM167B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FAM167B Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for biochemical assays. |
View FAM167B Products |
| Gene Delivery | FAM167B Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic validation. |
View FAM167B Products |
| Benchmark Ab | Anti-FAM167B Antibody Recombinant positive control for expression verification and IHC/WB assays. |
View FAM167B Products |
| Validator | FAM167B siRNA Set For target knockdown and specificity verification in functional assays. |
View FAM167B Products |
| Related Target A | DIXDC1 Direct intracellular interaction partner of FAM167B, crucial for Wnt pathway modulation. |
View DIXDC1 Products |
| Related Target B | CTNNB1 (Beta-Catenin) Downstream effector of Wnt signaling, essential for checking signaling cascade changes. |
View CTNNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein-Protein Interaction (PPI) screening | High-purity recombinant FAM167B with precise tag options (His/GST) for robust SPR/MST assays |
| Stable expression in target cell lines | Lentiviral particles sequence-verified for native-like mammalian intracellular expression |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live FAM167B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FAM167B therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors and protein-protein interaction (PPI) disruptors. As first-generation therapies reach the clinic, the next wave of R&D is targeting downstream signaling blockades and combination strategies to bypass resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Disruptor) | Biotech Startups, Academic Consortia | Solid Tumors (Lung, Breast Cancer) | Biochemical Binding Assay (Need high-purity recombinant protein) |
| siRNA / RNAi Therapeutics | RNAi Specialists | Metastatic Cancers | Target Knockdown Validation (Need validated siRNA and Lentivirus) |
| Targeted Protein Degradation (PROTAC) | Oncology-focused Biopharma | Refractory Tumors | Ubiquitination & Degradation Assay (Need stable cell lines and verified antibodies) |